OS Therapies (NYSEAMERICAN:OSTX) Earns "Buy" Rating from D. Boral Capital

Key Points

• D. Boral Capital reaffirmed a "Buy" rating on OS Therapies and set a $20.00 price objective, far above the current share price.
• Shares opened at $1.23 (down 3.1%), the company has a market cap of about $48.6M and reported a ($0.41) loss per share last quarter with analysts forecasting -$0.64 for the year, underscoring its high-risk, speculative profile.
• OS Therapies is a clinical-stage biopharmaceutical focused on osteosarcoma, with lead programs including OST-HER2 immunotherapy and an OST-tADC antibody‑drug conjugate platform.

OS Therapies (NYSEAMERICAN:OSTX - Get Free Report)'s stock had its "buy" rating reaffirmed by stock analysts at D. Boral Capital in a research report issued on Wednesday,Benzinga reports. They presently have a $20.00 price objective on the stock.

OS Therapies Stock Down 3.1%

OS Therapies stock opened at $1.23 on Wednesday. The company's 50-day moving average price is $1.38 and its 200-day moving average price is $1.63. OS Therapies has a twelve month low of $1.12 and a twelve month high of $2.57. The company has a market cap of $48.62 million, a PE ratio of -1.24 and a beta of -2.98.

OS Therapies (NYSEAMERICAN:OSTX - Get Free Report) last posted its earnings results on Tuesday, March 31st. The company reported ($0.41) earnings per share for the quarter. As a group, sell-side analysts expect that OS Therapies will post -0.64 earnings per share for the current fiscal year.

Institutional Trading of OS Therapies

Large investors have recently made changes to their positions in the business. Susquehanna International Group LLP bought a new stake in shares of OS Therapies in the 3rd quarter worth about $29,000. Mercer Global Advisors Inc. ADV purchased a new position in shares of OS Therapies during the 3rd quarter worth about $40,000. Ground Swell Capital LLC purchased a new position in shares of OS Therapies during the 3rd quarter worth about $40,000. Bridgeway Capital Management LLC purchased a new position in shares of OS Therapies during the 2nd quarter worth about $47,000. Finally, Jane Street Group LLC purchased a new stake in OS Therapies in the 4th quarter valued at about $39,000.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.